Detail
| LncRNA Name | LINC00152 |
| Synonyms | CYTOR, C2orf59, LINC00152, NCRNA00152, MGC4677 |
| Region | GRCh38_2:87454781-87636740 Sequence |
| Ensembl | ENSG00000222041 |
| RefSeq | NR_024204 |
| Circulating | ✘ |
| Drug-resisitant | ✔ |
| Prognostic | ✘ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot etc. |
| Sample | breast cancer tissues, cell line (SKBR3, MDA-MB-231, and MCF-7), |
| Expression Pattern | up-regulated |
| Function Description | The results showed that Linc00152 was highly expressed in the breast cancer tissues compared to their adjacent normal tissues, and Linc00152 was also up-regulated in the breast cancer cell lines compared to normal cell lines. Knock-down of Linc00152 by using siRNAs in breast cancer cell lines (MDA-MB-231 and MCF-7) significantly suppressed cell viability, cell growth, cell invasion and migration as measured by the CCK-8, colony formation, transwell invasion, and migration assays. The qRT-PCR and Western blot results showed that knock-down of Linc00152 suppressed epithelial-mesenchymal transition in breast cancer cell lines. In addition, CCK-8 assay showed that knock-down of Linc00152 in MCF-7/ADR cells reversed the chemo-resistance to doxorubicin. |
| Pubmed ID | 29863253 |
| Year | 2018 |
| Title | Down-regulation of lncRNA Linc00152 suppressed cell viability, invasion, migration, and epithelial to mesenchymal transition, and reversed chemo-resistance in breast cancer cells. |
| External Links |
| Links for LINC00152 | GenBank HGNC lncrnadb Noncode |
| Links for breast cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.